Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ATM NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATMRio2C$0.68+1.5%C$0.68C$0.57▼C$0.86C$57.62MN/A114,654 shs15,000 shsKODKodiak Sciences$32.94-3.3%$39.01$3.43▼$47.84$2.13B2.21669,364 shs412,885 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATMRio20.00%0.00%0.00%0.00%0.00%KODKodiak Sciences0.00%+15.03%-8.00%+42.81%+777.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATMRio2C$0.68+1.5%C$0.68C$0.57▼C$0.86C$57.62MN/A114,654 shs15,000 shsKODKodiak Sciences$32.94-3.3%$39.01$3.43▼$47.84$2.13B2.21669,364 shs412,885 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATMRio20.00%0.00%0.00%0.00%0.00%KODKodiak Sciences0.00%+15.03%-8.00%+42.81%+777.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATMRio2 0.00N/AN/AN/AKODKodiak Sciences 2.63Moderate Buy$42.1427.94% UpsideCurrent Analyst Ratings BreakdownLatest BZT, ATM, 1SN, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.003/27/2026KODKodiak Sciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.003/27/2026KODKodiak Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00 ➝ $58.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATMRio2N/AN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATMRio2N/AN/AN/AN/AN/AN/AN/AN/AN/AKODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)Latest BZT, ATM, 1SN, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATMRio2N/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATMRio2N/AN/AN/AKODKodiak SciencesN/A3.543.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATMRio2N/AKODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipATMRio2N/AKODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATMRio2N/A84.74 millionN/ANot OptionableKODKodiak Sciences9062.58 million33.86 millionOptionableBZT, ATM, 1SN, and KOD HeadlinesRecent News About These CompaniesKodiak Sciences: Clinical Redemption Is Turning Into Platform LeverageJune 16 at 1:01 PM | seekingalpha.comKodiak Sciences Inc. (NASDAQ:KOD) Receives $42.14 Consensus Price Target from BrokeragesJune 13 at 3:42 AM | americanbankingnews.comKodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should KnowJune 9, 2026 | fool.comKodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing PlansJune 7, 2026 | finance.yahoo.comKodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 5, 2026 | seekingalpha.comKodiak Sciences Stockholders Back Directors and Governance ProposalsJune 4, 2026 | tipranks.comKodiak Stock Rises 35% in 3 Months: Here's What You Need to KnowJune 4, 2026 | zacks.comKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | prnewswire.comWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping RallyMay 17, 2026 | fool.comKodiak Sciences (KOD) price target increased by 16.91% to 66.30May 14, 2026 | msn.comChardan Capital upgrades Kodiak Sciences (KOD)May 11, 2026 | msn.comA Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For ZenkudaMay 11, 2026 | finance.yahoo.comZenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)May 10, 2026 | finance.yahoo.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 8, 2026 | finanznachrichten.deKodiak's Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 8, 2026 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesApril 30, 2026 | prnewswire.comKodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?April 30, 2026 | zacks.comKodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?April 24, 2026 | finance.yahoo.comKodiak Sciences (NASDAQ:KOD) Signals Behind Surge Points To MomentumApril 16, 2026 | kalkinemedia.comKNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026BZT, ATM, 1SN, and KOD Company DescriptionsRio2 CVE:ATMC$0.68 +0.01 (+1.49%) As of 07/26/2018Atacama Pacific Gold Corporation, an exploration stage company, engages in the acquisition, exploration, and development of gold properties in Chile. The company principally holds a 100% interest in the Cerro Maricunga gold project located in Region III northeast of the city of Copiapo. Atacama Pacific Gold Corporation was incorporated in 2008 and is headquartered in Toronto, Canada.Kodiak Sciences NASDAQ:KOD$32.94 -1.12 (-3.29%) Closing price 04:00 PM EasternExtended Trading$32.92 -0.02 (-0.06%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
